同和药业(300636) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥186,897,547.53, representing a decrease of 9.47% compared to ¥206,454,983.02 in the same period last year[5] - Net profit attributable to shareholders was ¥20,781,376.97, down 52.30% from ¥43,562,751.14 year-on-year[5] - Basic and diluted earnings per share decreased by 52.27% to ¥0.0495 from ¥0.1037 in the same period last year[5] - The operating profit for the current period is CNY 22,045,134.74, down from CNY 49,031,953.90, reflecting a decline of 55.1%[23] - The total comprehensive income attributable to the parent company is CNY 20,781,376.97, down from CNY 43,562,751.14 in the previous period[23] Cash Flow - The net cash flow from operating activities increased by 19.91% to ¥35,664,255.22, compared to ¥29,743,589.13 in the previous year[11] - Cash flow from operating activities generated a net amount of CNY 35,664,255.22, an increase of 19.7% from CNY 29,743,589.13 in the previous period[25] - The net cash flow from investing activities increased by 110.82% to ¥16,089,848.66, compared to a negative cash flow of ¥148,676,249.14 in the previous year[11] - Cash flow from investing activities yielded a net inflow of CNY 16,089,848.66, compared to a net outflow of CNY 148,676,249.14 in the previous period[25] - Cash flow from financing activities resulted in a net inflow of CNY 78,708,229.72, up from CNY 150,196,833.20 in the previous period[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,421,287,186.43, an increase of 3.06% from ¥3,319,551,672.71 at the end of the previous year[5] - Total liabilities increased to ¥1,091,757,923.63 from ¥1,010,803,786.88, reflecting an increase of 8.0%[20] - The company's cash and cash equivalents increased to ¥306,214,227.30 from ¥176,384,468.01, representing a growth of 73.5%[19] - Total cash and cash equivalents at the end of the period amounted to CNY 296,214,227.30, down from CNY 525,619,976.92 in the previous period[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,278[13] - The largest shareholder, Pang Zhengwei, holds 14.71% of shares, totaling 62,027,337 shares, with 46,520,503 shares under pledge[13] - The second largest shareholder, Fenglong Industrial Co., Ltd., holds 13.17% of shares, totaling 55,511,352 shares[13] - The top ten shareholders collectively hold significant stakes, with the largest three shareholders accounting for 29.58% of total shares[13] Research and Development - Research and development expenses rose by 37.39% to ¥14,140,941.15, primarily due to increased labor costs and material consumption[10] - Research and development expenses rose significantly to ¥14,140,941.15, compared to ¥10,292,403.05 in the previous period, reflecting a 37.4% increase[22] - The company is currently undergoing internal renovations for the quality inspection and research and development building[17] Operational Insights - Total operating revenue for the current period is ¥186,897,547.53, a decrease of 9.4% from ¥206,454,983.02 in the previous period[22] - Total operating costs increased to ¥161,677,017.83, up 7.0% from ¥150,662,133.88 in the previous period[22] - The company's net profit margin is under pressure due to rising costs, with operating costs outpacing revenue growth[22] - The company has maintained a stable equity position, with total equity increasing to ¥2,329,529,262.80 from ¥2,308,747,885.83, a growth of 0.9%[21] Future Plans - The company has completed the main equipment procurement for the expansion project in the second factory area, with installation underway[17] - The company plans to implement new, modified, and expanded projects in the second factory area, which have been approved by the shareholders[17] - The company is focusing on market expansion and new product development as part of its strategic initiatives moving forward[22] Stock Information - The total number of restricted shares at the beginning of the period was 57,109,218, with 2,986,962 shares released during the period[16] - The number of unrestricted shares held by the top ten unrestricted shareholders totals 55,511,352 shares[14] - The company has a stock incentive plan with a vesting period of 12, 24, and 36 months for certain shares[16] Taxation - The company reported a significant decrease in income tax expenses by 76.61%, amounting to ¥1,263,808.79 compared to ¥5,402,452.76 in the same period last year[10] - The company experienced a 164.80% increase in taxes and surcharges, amounting to ¥2,274,797.03, primarily due to an increase in value-added tax surcharges[10] Audit Status - The company has not yet audited the first quarter report for the current year[27]